UPDATE: Deutsche Bank Starts ABIOMED (ABMD) at Buy, 'Size Matters'

Deutsche Bank analyst Pito Chickering initiates coverage on ABIOMED (NASDAQ: ABMD) with a Buy rating and a price target of $360.00.

The analyst comments "ABMD is one of the most controversial names within our Medtech coverage universe. Over the past decade, there have been multiple debates on how useful the Impella pump is versus a standard balloon pump; then the debate shifted to reimbursement concerns and CMS potentially cutting payment rates; and then recently, it has shifted back to questions around Impella’s effectiveness. Despite these concerns on Wall Street, company revenues have grown from $100m in 2011 to $847m in 2021, which we believe shows the underlying demand from physicians and clinical merits of the technology."

For an analyst ratings summary and ratings history on ABIOMED click here. For more ratings news on ABIOMED click here.

Shares of ABIOMED closed at $312.61 yesterday.

You May Also Be Interested In

• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• Cantor Fitzgerald Reiterates Overweight Rating on Merlin Labs (MRLN)
• SoundThinking (SSTI) PT Lowered to $8 at Cantor Fitzgerald